S B Strauss1, J E Lantos1, L A Heier1, D R Shatzkes2, C D Phillips3. 1. From the Department of Radiology (S.B.S., J.E.L., L.A.H., C.D.P.), Weill Cornell Medical College, New York-Presbyterian, New York, New York. 2. Department of Radiology (D.R.S.), Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital and The New York Head and Neck Institute, New York, New York. 3. From the Department of Radiology (S.B.S., J.E.L., L.A.H., C.D.P.), Weill Cornell Medical College, New York-Presbyterian, New York, New York cdp2001@med.cornell.edu.
Abstract
BACKGROUND AND PURPOSE: Unique among the acute neurologic manifestations of Severe Acute Respiratory Syndrome coronavirus 2, the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, is chemosensory dysfunction (anosmia or dysgeusia), which can be seen in patients who are otherwise oligosymptomatic or even asymptomatic. The purpose of this study was to determine if there is imaging evidence of olfactory apparatus pathology in patients with COVID-19 and neurologic symptoms. MATERIALS AND METHODS: A retrospective case-control study compared the olfactory bulb and olfactory tract signal intensity on thin-section T2WI and postcontrast 3D T2 FLAIR images in patients with COVID-19 and neurologic symptoms, and age-matched controls imaged for olfactory dysfunction. RESULTS: There was a significant difference in normalized olfactory bulb T2 FLAIR signal intensity between the patients with COVID-19 and the controls with anosmia (P = .003). Four of 12 patients with COVID-19 demonstrated intraneural T2 signal hyperintensity on postcontrast 3D T2 FLAIR compared with none of the 12 patients among the controls with anosmia (P = .028). CONCLUSIONS: Olfactory bulb 3D T2 FLAIR signal intensity was greater in the patients with COVID-19 and neurologic symptoms compared with an age-matched control group with olfactory dysfunction, and this was qualitatively apparent in 4 of 12 patients with COVID-19. Analysis of these preliminary finding suggests that olfactory apparatus vulnerability to COVID-19 might be supported on conventional neuroimaging and may serve as a noninvasive biomarker of infection.
BACKGROUND AND PURPOSE: Unique among the acute neurologic manifestations of Severe Acute Respiratory Syndrome coronavirus 2, the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, is chemosensory dysfunction (anosmia or dysgeusia), which can be seen in patients who are otherwise oligosymptomatic or even asymptomatic. The purpose of this study was to determine if there is imaging evidence of olfactory apparatus pathology in patients with COVID-19 and neurologic symptoms. MATERIALS AND METHODS: A retrospective case-control study compared the olfactory bulb and olfactory tract signal intensity on thin-section T2WI and postcontrast 3D T2 FLAIR images in patients with COVID-19 and neurologic symptoms, and age-matched controls imaged for olfactory dysfunction. RESULTS: There was a significant difference in normalized olfactory bulb T2 FLAIR signal intensity between the patients with COVID-19 and the controls with anosmia (P = .003). Four of 12 patients with COVID-19 demonstrated intraneural T2 signal hyperintensity on postcontrast 3D T2 FLAIR compared with none of the 12 patients among the controls with anosmia (P = .028). CONCLUSIONS: Olfactory bulb 3D T2 FLAIR signal intensity was greater in the patients with COVID-19 and neurologic symptoms compared with an age-matched control group with olfactory dysfunction, and this was qualitatively apparent in 4 of 12 patients with COVID-19. Analysis of these preliminary finding suggests that olfactory apparatus vulnerability to COVID-19 might be supported on conventional neuroimaging and may serve as a noninvasive biomarker of infection.
Authors: Jerome R Lechien; Carlos M Chiesa-Estomba; Daniele R De Siati; Mihaela Horoi; Serge D Le Bon; Alexandra Rodriguez; Didier Dequanter; Serge Blecic; Fahd El Afia; Lea Distinguin; Younes Chekkoury-Idrissi; Stéphane Hans; Irene Lopez Delgado; Christian Calvo-Henriquez; Philippe Lavigne; Chiara Falanga; Maria Rosaria Barillari; Giovanni Cammaroto; Mohamad Khalife; Pierre Leich; Christel Souchay; Camelia Rossi; Fabrice Journe; Julien Hsieh; Myriam Edjlali; Robert Carlier; Laurence Ris; Andrea Lovato; Cosimo De Filippis; Frederique Coppee; Nicolas Fakhry; Tareck Ayad; Sven Saussez Journal: Eur Arch Otorhinolaryngol Date: 2020-04-06 Impact factor: 2.503
Authors: A Boscutti; G Delvecchio; A Pigoni; G Cereda; V Ciappolino; M Bellani; P Fusar-Poli; P Brambilla Journal: Brain Behav Immun Health Date: 2021-05-18
Authors: M F V V Aragao; P H P deAndrade; V S da Nobrega Segundo; M M Marques; H J G de Azevedo; R J V de Mello; M de Carvalho Leal; M L Soares; M M Valenca Journal: AJNR Am J Neuroradiol Date: 2021-08-05 Impact factor: 4.966
Authors: K M Capaccione; H Yang; E West; H Patel; H Ma; S Patel; A Fruauff; G Loeb; A Maddocks; A Borowski; S Lala; P Nguyen; A Lignelli; B D'souza; E Desperito; C Ruzal-Shapiro; M M Salvatore Journal: Acad Radiol Date: 2021-02-04 Impact factor: 3.173
Authors: Permesh Singh Dhillon; Robert A Dineen; Haley Morris; Radu Tanasescu; Esmaeil Nikfekr; Jonathan Evans; Cris S Constantinescu; Akram A Hosseini Journal: Front Neurol Date: 2021-02-19 Impact factor: 4.086
Authors: Michael S Xydakis; Mark W Albers; Eric H Holbrook; Dina M Lyon; Robert Y Shih; Johannes A Frasnelli; Axel Pagenstecher; Alexandra Kupke; Lynn W Enquist; Stanley Perlman Journal: Lancet Neurol Date: 2021-07-30 Impact factor: 44.182